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Type 1 diabetes (T1D) is a debilitating chronic autoimmune
disease (AID) for which there is currently no preventive
treatment or therapeutic strategies. Patients with T1D are
also at higher risk for other autoimmune disease such as
celiac disease. In genetically susceptible individuals, T1D is
associated with the generation and activation of autoreactive
CD4+ and CD8+ T cells that inﬁltrate the pancreas and
selectively destroy the insulin-producing β-cells in the islets.
TheimpairmentofT-celltoleranceinT1Dhasbeenreported
at many levels including abnormal self-antigen presentation
in the thymus and periphery, autoreactive T-cell resistance
to apoptosis, unbalanced immunoregulatory T-cell function,
and deregulation of Th1/Th2/Th17 axes. Despite the iden-
tiﬁcation of T1D-associated autoantigens and their derived
CD4+ and CD8+ T-cell epitopes, numerous antigen-speciﬁc
immunoregulatory therapies have failed when evaluated for
their eﬃciency in the prevention and treatment of T1D.
The development of antigen-speciﬁc tolerization approaches
to treat or to prevent T1D would bring exceptionally high
economic and health beneﬁts. In this special issue, we
accepted original research and review articles highlight-
ing the recent advances in T1D-associated immunological
tolerance mechanisms and potential immunotherapeutic
strategies.
In the ﬁrst paper of this special issue, A. A. Chentouﬁ
and V. Geenen have addressed the role of thymic self-
antigens expression in the control of self-reactive and
regulatory T-cells generation. Also, the authors proposed the
concept of negative/tolerogenic self-vaccination to modulate
diabetogenic autoimmune responses. In the second paper,
G. F. Hoyne described the molecular mechanisms that
regulate peripheral immune responses that control organ-
speciﬁc autoimmunity and highlighted the role of a range
of E3 ubiquitin ligases and signaling pathways that inﬂuence
the development of eﬀector T-cell responses and T1D
development. The third paper by A. A. Chentouﬁ et al.
highlighted the recent ﬁndings and controversies regarding
the tolerogenic properties of interleukin-2 (IL-2) mediated
through naturally occurring regulatory T cells and discussed
thelinkbetweentheimmunomodulatoryroleofIL-2andthe
pathogenesis of T1D.
In the fourth paper of this special issue, the group of A.
Amrani eloquently investigated the abnormal functionality
of dendritic cells (DCs) in nonobese diabetic (NOD) mice
through the expression of IRF4 and IRF8 genes. The
results showed an upregulation of IRF4, but not IRF8,
expression in CD11c+ splenic DCs of NOD as compared
to BALB/c mice and correlated with the increased levels
of CD4+CD8α− DCs suggesting that IRF4 may be involved
in abnormal DC functions in diabetes in NOD mice. In
the ﬁfth paper, the group of G. A. Passos investigated
the transcriptional modulation of immune reactivity genes
occurring through thymocytes maturation into peripheral
autoreactive T lymphocytes. The transcriptome of thymo-
cytes and peripheral CD3+ T lymphocytes from prediabetic
or diabetic mice analyzed through microarray hybridizations
identiﬁed 2,771 diﬀerentially expressed genes. The analysis
of the transcriptional activity of thymocytes developing into
peripheral T cells revealed sequential participation of genes
involved in CD4+/CD8+ Tc e l ld i ﬀerentiation, tolerance2 Clinical and Developmental Immunology
induction by regulatory T cells, and apoptosis soon after T-
cell activation, while the emergence of T1D coincided with
the expression of cytotoxicity and inﬂammatory response
genes by peripheral T lymphocytes. The sixth paper by
M. Delmastro and J. Piganelli described the importance of
reactiveoxygenspecies/oxidativestressaswellaspotentialfor
redox modulation in the context of T1D.
In the following selected research article papers, P. Alard
and Y. Zhang groups described novel therapeutic approaches
that prevent and/or treat T1D in mouse model. Indeed, P.
Alard group have proposed to utilize the microorganism
ability to induce tolerogenic DCs to abrogate the proin-
ﬂammatory process and prevent diabetes development. They
have shown that LTA-treated DCs produced much more IL-
12 than IL-10 and accelerated diabetes development when
transferred into NOD mice. In contrast, stimulation of NOD
DCs with L. Casei favored the production of IL-10 over
IL-12, and their transfer decreased disease incidence in an
IL-10-dependent manner. Similarly, Y. Zhang group have
shown that oral administration of the CTB-Ins-GFP protein
induced tolerance, delayed the development of diabetic
symptoms, and suppressed diabetes onset in NOD mice.
Furthermore, CTB-Ins-GFP protein increased the numbers
of CD4+CD25+Foxp3+ regulatory T cells in peripheral
lymph tissues and aﬀected the biological activity of spleen
cells.
In the last series of papers, we have selected review
papers describing the antigen-based therapeutic approaches.
S. Culina et al. have discussed the diﬀerent antigen
formulations that have been considered for T1D treat-
ment/prevention, such as proteins or peptides, either in their
native form or modiﬁed ad hoc, DNA plasmids, and cell-
based agents. Also, they highlighted the diﬀerences between
mice model and human data that should be taken into
account. Critical parameters such as administration route,
dosing, and interval remain largely empirical and need to be
further dissected. R. Mallone et al. described T-cell recogni-
tion of autoantigens in human T1D and their relevance to
the clinical perspective. Finally, B. Philips et al. highlighted
the preclinical successes and the excitement generated by
phase I trials while oﬀering alternative possibilities and new
translational avenues that can be explored given the very
recent disappointment in leading agents in more advanced
clinical trials.
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